# Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet

> **NCT05886933** · — · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 9846 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Fexuprazan Hydrochloride

## Key facts

- **NCT ID:** NCT05886933
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-22
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 9846 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886933, "Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05886933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*